Kennedy Overhauls Federal Autism Panel in His Own Image

Health Secretary Robert F. Kennedy Jr. on Jan. 29, 2026 announced a wholesale reshaping of the Interagency Autism Coordinating Committee (IACC), the federal advisory group that helps set research and services priorities for people with autism. The new roster replaces the committee’s previous public members with 21 appointees who include outspoken vaccine critics, a former staffer for a Kennedy-aligned super PAC, clinicians and parents who have publicly linked vaccines to their children’s diagnoses. The committee will advise federal agencies on how to allocate roughly $2 billion in congressional funding for autism research and services over the next five years. Although the IACC holds only advisory authority, longtime advocates and many researchers said the new composition raises concerns about agenda-setting and scientific credibility.

• Robert F. Kennedy Jr. announced 21 new public members for the Interagency Autism Coordinating Committee on Jan. 29, 2026; the committee also includes 21 government members from multiple federal agencies.
• The IACC, created in 2000, will advise on priorities for approximately $2 billion Congress directed toward autism research and services for the coming five-year period.
• Several appointees are publicly known for arguing that vaccines cause autism; others include a former super PAC employee, a physician previously sued over heavy-metal therapies, and a political economist who has testified against vaccines in Congress.
• Advocates and many scientists warn that appointing vaccine-critical members risks shifting discussion away from mainstream, evidence-based research priorities.
• Alison Singer, IACC member from 2007 to 2019 and head of the Autism Science Foundation, said the new panel does not reflect the broader autism community and overrepresents a small subset of families.
• The committee’s meetings are public, but its recommendations are advisory only; federal agencies retain statutory authority over funding decisions.

Background

The Interagency Autism Coordinating Committee was established in 2000 to bring together autistic people, family members, scientists, clinicians and federal officials to coordinate autism research and services across agencies. Over two decades the IACC served as a forum for balancing research priorities — from basic neuroscience to community services — and for offering guidance on how federal dollars should be distributed. Congress this cycle designated roughly $2 billion to be directed toward autism work over five years, amplifying the advisory panel’s potential influence on priorities and public conversation. Historically the committee’s public members reflected a range of perspectives; the new slate marks a sharp change in composition and has prompted immediate scrutiny from established advocacy groups and researchers.

Appointments to advisory bodies typically reflect the health secretary’s policy priorities, but the scale and one-sided nature of this replacement is notable. The new public members include individuals with documented ties to Mr. Kennedy’s presidential campaign and to advocacy that attributes autism to vaccines and environmental toxins. Those positions run counter to the consensus of multiple large-scale epidemiological studies conducted over the last two decades that have not found a causal link between routine childhood vaccines and autism. Federal agencies, however, have limited power to veto advisory appointments, making the committee’s membership a consequential channel for shaping agenda-setting and public debate.

Main Event

On Jan. 29, 2026 (updated 7:32 p.m. ET), the Health and Human Services leadership announced the replacement of all public members on the IACC with 21 new appointees. The announcement identified the panel’s statutory role — to advise federal agencies on research and services for people on the autism spectrum — and listed the new roster categories but provided limited detail on intended priorities. Among the appointees are parents who publicly attribute their children’s autism to vaccines, a physician who has faced litigation over administering heavy-metal chelation treatments to a child with autism, and a political economist who previously testified before Congress raising vaccine safety concerns.

Advocacy groups and researchers reacted quickly. Some longtime members described the new composition as skewed toward a specific, vaccine-focused viewpoint and warned that the committee could prioritize investigations and policy recommendations that fall outside mainstream scientific consensus. At the same time, supporters of the changes framed them as correcting perceived institutional bias against exploring environmental and vaccine-related hypotheses. The IACC’s six-year track record of public meetings and written strategic plans means any shift in membership can change which questions receive attention and which research gaps are highlighted.

Operationally, the committee will continue to meet publicly and produce recommendations for federal agencies. But because the IACC is advisory, its influence depends on the willingness of agencies such as the National Institutes of Health, the Centers for Disease Control and Prevention and the Substance Abuse and Mental Health Services Administration to act on its guidance. The practical question now is whether the newly constituted IACC will pursue recommendations that lead agencies to alter funding priorities, and if so, how quickly agencies will respond.

Analysis & Implications

The abrupt reconstitution of the IACC has three immediate implications. First, it shifts public attention: a panel that previously focused on a broad portfolio of autism research areas may now spotlight vaccine and environmental hypotheses, altering media and philanthropic agendas. Second, it risks eroding trust between mainstream researchers and the panel; many scientists worry that legitimizing fringe positions in a federal advisory forum could confuse the public about established evidence. Third, the change could affect translational services funding if the committee’s recommendations prioritize different types of interventions or surveillance activities.

From a policy standpoint the IACC’s advisory status limits direct damage, but advisory recommendations shape agency priorities, requests for proposals, and the framing of research questions. If agencies incorporate the panel’s guidance, we could see more resources steered toward studies examining environmental risk factors and vaccine-related questions, potentially at the expense of service delivery research, community-based interventions and neuroscientific work. Reallocating limited funds carries opportunity costs that would have downstream effects on clinical practice, state service systems and family supports.

Politically, the reshuffle reflects the secretary’s broader agenda and signals an intent to reframe federal engagement with autism policy. That may mobilize constituencies on both sides: families and advocates who feel marginalized by mainstream institutions might welcome what they see as federal acknowledgement, while scientific and clinical communities may push back to defend evidence-based standards. On the international stage, the move could influence how other governments and multilateral bodies view U.S. autism policy and research priorities, given the United States’ outsized role in funding biomedical research.

Comparison & Data

The IACC has historically combined public stakeholders and federal officials to create shared priorities. The new composition — 21 public members with a sizable number known for vaccine-skeptical positions — represents a departure from earlier, more heterogeneous rosters. That change, coupled with the $2 billion funding envelope, raises questions about whether the balance of research topics funded over the next five years will shift noticeably. Stakeholders should watch agency budget announcements, requests for proposals, and the IACC’s meeting agendas for concrete signs of reprioritization.

Reactions & Quotes

Several established autism organizations and past committee members expressed alarm.

“The new committee does not represent the autism community.”

Alison Singer, Autism Science Foundation; IACC member 2007–2019

Public-health and scientific observers emphasized the committee’s limited legal authority while cautioning that advisory bodies can nonetheless shift public discourse.

“The panel serves only an advisory role to federal agencies, not a binding decision-maker on funding allocations.”

IACC committee description / federal advisory norms

Unconfirmed

• Whether federal agencies will adopt any specific IACC recommendations from the new membership remains unknown and will depend on agency reviews of proposals and alignment with existing statutory mandates.
• The degree to which individual new appointees will push for particular research lines or policy changes has not been publicly documented in detail.
• Any prosecution, litigation outcomes, or formal findings related to specific clinicians named among appointees were summarized from reporting and are subject to further verification.

Bottom Line

Robert F. Kennedy Jr.’s reconstitution of the IACC is a significant policy signal: it places vaccine-skeptical and environmental-focused voices into a federal advisory forum at a moment when Congress has allocated roughly $2 billion for autism work. Because the committee is advisory, the immediate legal impact is limited; however, advisory bodies shape research agendas, influence public debate and can affect which grant topics receive emphasis. Stakeholders should monitor agency responses, upcoming IACC meeting agendas, and solicitation language in federal funding notices to see how priorities evolve.

For families, researchers and service providers, the key watchpoints are concrete changes in funding solicitations and program guidance. If agencies adopt recommendations that redirect funds toward contested hypotheses, there will be both scientific and practical consequences for the distribution of scarce resources. The coming months will reveal whether this overhaul produces policy shifts, mere rhetorical changes, or intensified debates between advocates and the scientific community.

Sources

• The New York Times (news reporting) — original coverage of the Jan. 29, 2026 IACC appointments and reactions